Page 5 - 09 EMA
P. 5
ndication
units for males). Abseamed can be used to reduce exposure to allogeneic
blood transfusions in adult non iron deficient patients prior to major
lective orthopaedic surgery, having a high perceived risk for
ransfusion complications. Use should be restricted to patients with
moderate anaemia (e.g. Hb 10-13 g/dl) who do not have an autologous
predonation programme available and with an expected blood loss of 900
o 1800 ml.
Accofil is indicated for the reduction in the duration of neutropenia and
he incidence of febrile neutropenia in patients treated with established
ytotoxic chemotherapy for malignancy (with the exception of chronic
myeloid leukaemia and myelodysplastic syndromes) and for the
eduction in the duration of neutropenia in patients undergoing
myeloablative therapy followed by bone marrow transplantation
onsidered to be at increased risk of prolonged severe neutropenia. The
afety and efficacy of Accofil are similar in adults and children receiving
ytotoxic chemotherapy.
Accofil is indicated for the mobilization of peripheral blood progenitor
ells (PBPCs).In patients, children or adults with severe congenital,
yclic, or idiopathic neutropenia with an absolute neutrophil count
ANC) of 0.5 x 109/L, and a history of severe or recurrent infections, long
erm administration of Accofil is indicated to increase neutrophil counts
and to reduce the incidence and duration of infection-related events.
Accofil is indicated for the treatment of persistent neutropenia (ANC
ess than or equal to 1.0 x 109/L) in patients with advanced HIV
nfection, in order to reduce the risk of bacterial infections when other
ptions to manage neutropenia are inappropriate.
n adult women
Anovulation (including polycystic ovarian disease, PCOD) in
women who have been unresponsive to treatment with
clomiphene citrate
Stimulation of multifollicular development in patients
-3-
units for males). Abseamed can be used to reduce exposure to allogeneic
blood transfusions in adult non iron deficient patients prior to major
lective orthopaedic surgery, having a high perceived risk for
ransfusion complications. Use should be restricted to patients with
moderate anaemia (e.g. Hb 10-13 g/dl) who do not have an autologous
predonation programme available and with an expected blood loss of 900
o 1800 ml.
Accofil is indicated for the reduction in the duration of neutropenia and
he incidence of febrile neutropenia in patients treated with established
ytotoxic chemotherapy for malignancy (with the exception of chronic
myeloid leukaemia and myelodysplastic syndromes) and for the
eduction in the duration of neutropenia in patients undergoing
myeloablative therapy followed by bone marrow transplantation
onsidered to be at increased risk of prolonged severe neutropenia. The
afety and efficacy of Accofil are similar in adults and children receiving
ytotoxic chemotherapy.
Accofil is indicated for the mobilization of peripheral blood progenitor
ells (PBPCs).In patients, children or adults with severe congenital,
yclic, or idiopathic neutropenia with an absolute neutrophil count
ANC) of 0.5 x 109/L, and a history of severe or recurrent infections, long
erm administration of Accofil is indicated to increase neutrophil counts
and to reduce the incidence and duration of infection-related events.
Accofil is indicated for the treatment of persistent neutropenia (ANC
ess than or equal to 1.0 x 109/L) in patients with advanced HIV
nfection, in order to reduce the risk of bacterial infections when other
ptions to manage neutropenia are inappropriate.
n adult women
Anovulation (including polycystic ovarian disease, PCOD) in
women who have been unresponsive to treatment with
clomiphene citrate
Stimulation of multifollicular development in patients
-3-
